Quantcast

Latest IgA nephropathy Stories

2014-07-28 20:24:33

HAYWARD, Calif., July 28, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014. Net loss for the three months ended June 30, 2014 was $7.3 million, compared to $8.3 million for the same period in 2013. The decrease in net loss is a direct result of a decrease in interest expense in the current period. Net loss for the six months ended June 30, 2014 was $15.2 million,...

2014-07-10 04:21:24

STOCKHOLM, July 10, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon(R) issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. Nefecon is a potential disease-modifying treatment for patients with primary IgA nephropathy at risk of developing end-stage renal disease. Nefecon has shown positive results in an...

2014-05-13 08:33:02

HAYWARD, Calif., May 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the first quarter ended March 31, 2014. First Quarter 2014 Financial Results: Net loss for the first quarter ended March 31, 2014 was $7.9 million, compared to $7.6 million for the same period in 2013. Operating expenses for the three months ended March 31, 2014 increased to $7.6 million from $6.9 million in the same period of...

2014-03-12 20:24:20

HAYWARD, Calif., March 12, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013. Fourth Quarter and Fiscal Year 2013 Financial Results: Net loss for the fourth quarter and year ended December 31, 2013 was $9.2 million and $30.9 million, respectively. Operating expense for the year ended December 31, 2013 was $28.2 million as compared to $55.9 million for...

2014-01-13 04:20:59

STOCKHOLM, January 13, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces it has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon(R) (http://www.nefigan.net). Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety...

2014-01-10 08:23:12

Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., Jan. 10, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below)....


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related